Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
NASDAQ Composite
Standard & Poors 500
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Cytodyn Inc
(OP:
CYDY
)
0.2220
-0.0068 (-2.97%)
Delayed Quote
Updated: 3:59 PM EST, Nov 20, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Cytodyn Inc
< Previous
1
2
3
4
5
Next >
CytoDyn Appoints Lauren Wilcoxen, Ph.D., as Chief Operating Officer and Head of Regulatory Affairs
November 17, 2026
From
CytoDyn Inc.
Via
GlobeNewswire
CytoDyn Announces $5 Million Private Investment to Advance Leronlimab in Colorectal Cancer and Other Solid Tumors
November 12, 2026
From
CytoDyn Inc.
Via
GlobeNewswire
CytoDyn and QLHC Advance Leronlimab into Two New PRE-I-SPY Studies in Metastatic Triple-Negative Breast Cancer
November 10, 2026
From
CytoDyn Inc.
Via
GlobeNewswire
CytoDyn Presents Updated Leronlimab Data in Metastatic Colorectal Cancer at ESMO Congress 2026
October 26, 2026
From
CytoDyn Inc.
Via
GlobeNewswire
CytoDyn Appoints Robert E. Hoffman as Chief Executive Officer
October 19, 2026
From
CytoDyn Inc.
Via
GlobeNewswire
CytoDyn to Host Investor Webcast
October 15, 2026
From
CytoDyn Inc.
Via
GlobeNewswire
CytoDyn to Present Updated Data from Phase 2 CLOVER Clinical Study at ESMO Congress 2026
October 08, 2026
From
CytoDyn Inc.
Via
GlobeNewswire
Life Sciences Virtual Investor Forum Presentations Now Available for On-Demand Viewing
September 18, 2026
Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.com
From
Virtual Investor Conferences
Via
GlobeNewswire
CytoDyn Inc. to Present at the Life Sciences Investor Forum on September 17th
September 15, 2026
From
Virtual Investor Conferences
Via
GlobeNewswire
Life Sciences Virtual Investor Forum Agenda Announced
September 14, 2026
Company executives will discuss their business strategies, provide updates on recent developments, and answer questions live from investors.
From
Virtual Investor Conferences
Via
GlobeNewswire
CytoDyn Closes $16.5 Million Financing to Fund Continued Development of Leronlimab
September 01, 2026
From
CytoDyn Inc.
Via
GlobeNewswire
CytoDyn Announces First Patient Dosed in Phase 2a Study in Collaboration with Weill Cornell Medicine Evaluating Leronlimab in Alzheimer’s Disease
June 11, 2026
From
CytoDyn Inc.
Via
GlobeNewswire
Natera and CytoDyn Announce Strategic Collaboration to Advance ctDNA-Guided Development and Molecular Response Analysis in Metastatic Colorectal Cancer
June 04, 2026
From
Natera, Inc.
Via
Business Wire
Platform Biotech Models Draw Investor Eyes as Drug-Delivery Markets Head Toward $410 Billion
June 03, 2026
Via
Investor Brand Network
NetworkNewsBreaks – Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Featured in BioMedWire Editorial on Advanced Drug Delivery and Platform-Based Biotech Innovation
June 03, 2026
Via
Investor Brand Network
Topics
Artificial Intelligence
Intellectual Property
Platform Biotech Models Draw Investor Eyes as Drug-Delivery Markets Head Toward $410 Billion
June 03, 2026
From
BioMedWire
Via
GlobeNewswire
CytoDyn to Present at the LD Micro Invitational XVI
May 15, 2026
From
CytoDyn Inc.
Via
GlobeNewswire
CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities
May 11, 2026
Via
Investor Brand Network
InvestorNewsBreaks – Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Targets CNS Drug Delivery Opportunity as Brain Therapeutics Innovation Accelerates
May 11, 2026
Via
Investor Brand Network
Topics
Intellectual Property
CytoDyn Announces First Patient Dosed in Expanded Access Program for Leronlimab in Triple-Negative Breast Cancer
April 27, 2026
From
CytoDyn Inc.
Via
GlobeNewswire
CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities
May 11, 2026
From
BioMedWire
Via
GlobeNewswire
CytoDyn to Host Investor Webcast
April 23, 2026
From
CytoDyn Inc.
Via
GlobeNewswire
CytoDyn Presents New Leronlimab Data in Metastatic Colorectal Cancer at AACR Annual Meeting 2026
April 22, 2026
From
CytoDyn Inc.
Via
GlobeNewswire
CytoDyn Completes Enrollment in Phase 2 Metastatic Colorectal Cancer Study
April 21, 2026
From
CytoDyn Inc.
Via
GlobeNewswire
CytoDyn Presents New Leronlimab Data in Metastatic Triple-Negative Breast Cancer at AACR Annual Meeting 2026
April 20, 2026
From
CytoDyn Inc.
Via
GlobeNewswire
CytoDyn to Present at the AACR Annual Meeting 2026
April 14, 2026
From
CytoDyn Inc.
Via
GlobeNewswire
CytoDyn Presents at AACR Special Conference in Cancer Research: Brain Cancer
March 24, 2026
From
CytoDyn Inc.
Via
GlobeNewswire
CytoDyn Closes $17.5 Million Financing to Fund Continued Development of Leronlimab
March 05, 2026
From
CytoDyn Inc.
Via
GlobeNewswire
CytoDyn Presents Novel CCR5 Inhibition Mechanisms and Long-Term Survival Signals for Leronlimab in Metastatic Breast Cancer at AACR Immuno-Oncology Conference
February 20, 2026
From
CytoDyn Inc.
Via
GlobeNewswire
CytoDyn Announces Funding and Initiation of Expanded Access Program for Patients with Triple-negative Breast Cancer
January 27, 2026
From
CytoDyn Inc.
Via
GlobeNewswire
< Previous
1
2
3
4
5
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit